Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Guinea Bissau Health Bulletin.
Press releases published on October 17, 2025
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL …
Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025
Presentations to highlight JADE101’s preclinical safety profile and translational framework guiding its clinical development in IgA nephropathy JADE101 is an investigational, potentially best-in-class disease-modifying anti-APRIL monoclonal antibody, with …
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
SOUTH SAN FRANCISCO, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on October 15, 2025 it granted stock options to purchase an aggregate of 109,120 shares of common stock and 73,535 restricted …
Targeted Alpha Therapies Market to Grow at 44% CAGR Globally by 2030
Boston, Oct. 17, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “Targeted Alpha Therapies for Cancer Treatment: Global Market” was valued at $199.6 million in 2024, and is expected to grow at a CAGR of 44% during the period 2025 …
ORYZON Receives Feedback From the FDA in Response to the Submitted Phase III Protocol in Borderline Personality Disorder
Provides clarity on the aspects to incorporate Company to address them and resubmit revised protocol MADRID, Spain and CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, BME: ORY), a clinical-stage …
XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement
- Amendment includes finalized cash amount and updated CVR terms for tender offer - LAVA announces new date for extraordinary general meeting of shareholders EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Penn., Oct. 17, 2025 (GLOBE …
Wake Radiology Grows Breast Imaging Section with Five New Hires; Launches "We See the Difference" Campaign for Breast Cancer Awareness Month
Raleigh, N.C., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Wake Radiology UNC Health Rex, the largest outpatient imaging provider in the Triangle, today announced the continued expansion of its breast imaging section with the addition of five new board-certified …
Valitor Appoints Biotech and Ophthalmic Industry Veteran Gregory D. Kunst as Chief Executive Officer
BERKELEY, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering a new generation of ophthalmic medicines, today announced the appointment of Gregory D. Kunst as chief executive officer and member of the board of directors. …
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
Company announcement – No. 22 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, October 17, 2025 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the …
Dr. Alyssa Dweck Shares Menopause Insights and Solutions on YourUpdateTV
NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- October is Menopause Awareness Month. Nearly half the population will go through it, yet menopause remains one of the most under-discussed health stages for women. During a recent satellite media tour in …
Silver Creek Pharmaceuticals Receives FDA Fast Track Designation for Scp776 in Acute Ischemic Stroke
Novel mechanism of action reverses and prevents death of injured cells Phase II ARPEGGIO trial fully enrolled Topline results to be presented at the World Stroke Congress, October 23, 2025 SOUTH SAN FRANCISCO, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- …
Artios Announces Phase 1/2a Data for DNA Polymerase Theta Inhibitor ART6043 at ESMO Congress 2025
Potential first-in-class, and industry-leading DNA polymerase Theta (Polθ) inhibitor, ART6043 demonstrated an attractive tolerability profile, expected PK/PD activity, and promising clinical signals Results support the potential advancement of ART6043 into …
Boehringer’s zongertinib demonstrated a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC
Ingelheim, Germany / Ridgefield, Connecticut, U.S. Data from the Phase Ib Beamion LUNG-1 trial evaluating zongertinib in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC were presented for the first time at ESMO 2025. Confirmed response by …
Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025
Trial is evaluating ciforadenant as a potential first line therapy for metastatic renal cell cancer (RCC) in combination with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) Interim data shows triplet therapy with ciforadenant, ipilimumab and nivolumab …
Protext Mobility, Inc. (OTC: TXTM) Announces Plans for Corporate Website Redesign and Investor Relations Suite to Enhance Transparency and Shareholder Engagement
NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Protext Mobility, Inc. (OTC: TXTM), an emerging leader in botanical-based biotechnology, today announced its strategic initiative to redesign its corporate website and develop a dedicated Investor Relations (IR) …
Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025
BRISBANE, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, …
WeightWatchers Launches RxFlexFund™, a New Employer Model for Expanding GLP-1 Coverage
NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers” or the “Company”), the global leader in science-backed weight management, today announced the launch of WeightWatchers RxFlexFund™, a first-of-its-kind …
Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week
WATERTOWN, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious …
Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show
GLEN ALLEN, Va., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related …